Your browser doesn't support javascript.
loading
Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
Sukeishi, Asami; Itohara, Kotaro; Yonezawa, Atsushi; Sato, Yuki; Matsumura, Katsuyuki; Katada, Yoshiki; Nakagawa, Takayuki; Hamada, Satoshi; Tanabe, Naoya; Imoto, Eishi; Kai, Shinichi; Hirai, Toyohiro; Yanagita, Motoko; Ohtsuru, Shigeru; Terada, Tomohiro; Ito, Isao.
Afiliação
  • Sukeishi A; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Itohara K; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Yonezawa A; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Sato Y; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
  • Matsumura K; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Katada Y; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Nakagawa T; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Hamada S; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Tanabe N; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Imoto E; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kai S; Shimadzu Corporation, Kyoto, Japan.
  • Hirai T; Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan.
  • Yanagita M; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Ohtsuru S; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Terada T; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
  • Ito I; Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
CPT Pharmacometrics Syst Pharmacol ; 11(1): 94-103, 2022 01.
Article em En | MEDLINE | ID: mdl-34793625
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina / Monofosfato de Adenosina / Alanina / Tratamento Farmacológico da COVID-19 / Nefropatias Tipo de estudo: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenosina / Monofosfato de Adenosina / Alanina / Tratamento Farmacológico da COVID-19 / Nefropatias Tipo de estudo: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article